Focus Partners Advisor Solutions LLC Grows Stock Holdings in Eli Lilly and Company $LLY

Focus Partners Advisor Solutions LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 21.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,238 shares of the company’s stock after acquiring an additional 2,828 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Eli Lilly and Company were worth $17,451,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $33,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the last quarter. Dorato Capital Management purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $36,000. Finally, New England Capital Financial Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $1,149.38 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.83, a PEG ratio of 1.24 and a beta of 0.53. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,182.73. The firm’s fifty day simple moving average is $979.60 and its two-hundred day simple moving average is $1,013.80.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Analyst Ratings Changes

LLY has been the topic of a number of recent analyst reports. Barclays increased their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Friday. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Finally, Leerink Partners set a $1,119.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage data for retatrutide showed strong weight-loss results and benefits for obesity-linked conditions, helping convince investors that Lilly can extend its lead in the fast-growing GLP-1 market. Reuters: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: Lilly also reported encouraging Phase 3 results for Foundayo (orforglipron), its oral GLP-1 drug, including better A1C control and weight loss than oral semaglutide in a head-to-head study, with FDA submission planned by the end of the second quarter. PR Newswire: Lilly’s oral GLP-1 Foundayo delivered superior A1C control and weight loss
• Positive Sentiment: Additional ADA conference updates showed Foundayo produced meaningful weight loss in women across menopause stages, broadening the potential patient population and supporting the drug’s commercial opportunity. PR Newswire: Foundayo associated with significant weight loss in women at every stage of menopause
• Positive Sentiment: Peer weakness also appears to be helping Lilly: Zealand Pharma’s disappointing GLP-1 data and a selloff in competing obesity names highlighted Lilly’s relative advantage in the weight-loss race. The Motley Fool: A Weight-Loss Rival Just Crashed 23%
• Neutral Sentiment: Lilly’s 340B deadline passed and hospitals are now evaluating the implications; this looks more like a policy/pricing issue than an immediate earnings catalyst. Becker’s Hospital Review: Eli Lilly’s 340B deadline passes
• Neutral Sentiment: Reports that Medicare’s GLP-1 bridge program may test Lilly’s obesity strategy add some uncertainty, but the impact is still unclear. MSN: Eli Lilly faces new test with Medicare GLP-1 Bridge program
• Neutral Sentiment: Lilly also completed a bioavailability study for early-stage asset LY4064809, which is a pipeline update but not likely a near-term stock driver. TipRanks: Lilly advances early-stage asset with completion of LY4064809 bioavailability study

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.